TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 22, 2019 | $340,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Oct 21, 2019 | $780,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
US-Mexico-Canada Agreement (issues relating to IP Chapter)
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOLLY A JUDGE | — |
| COLMAN BRENDAN RAGAN New | — |
Health Issues HCR
S.340/HR 965-Creating & Restoring Equal Access to Equivalent Samples Act ("Creates Act"); HR 985-Fast Generics Act; S.64-Preserve Access to Affordable Generic & Biosimilars Act; HR 1499-Protecting Consumer Access to Generic Drugs Act; HR 1344-Competitive Drugs Act of 2019; HR 938-Bringing Low Cost Options & Competition While Keeping Incentives for New Generics Act ("BLOCKING Act"); HR 1506-Fair & Immediate Release of Generic Drugs Act; HR 1520-Purple Book Continuity Act; HR 1503-Orange Book Transparency Act; S.344/HR 990-Hatch-Waxman Integrity Act; Stronger Patents Act; S.1895, Lower Health Care Costs Act; and Administration review of drug pricing policies.
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOLLY A JUDGE | — |
| COLMAN BRENDAN RAGAN New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.